Array Bridge is testing promising drug candidates that can effectively bind and even degrade target proteins, but not via their active sites.

About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven ...

Experimental drug NU-9—a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials ...

Cysts, fibrosis, and tubular degeneration form the typical triad of pathologies leading to the gradual decline in kidney ...

These appointments deepen the expertise and experience within the senior leadership as Myricx scales to becomes a clinical stage company, with multiple N-myristoyltransferase inhibitor ADCs (NMTi-ADC) ...

Shihabeddin et al utilized single-cell RNA-Seq analysis of adult P23H zebrafish animals to identify transcription factors (e2fs, Prdm1a, Sp1) expressed selectively in neural progenitors and immature ...

Antibodies were labeled by chloramine-T–catalyzed iodination and purified by gel-filtration chromatography on a PD-10 column (Sephadex G-25 M, Pharmacia Biotech, Uppsala). Binding of Ba/F3 ...

Apr. 9, 2025 — A new study has found that certain bacteria living in the nose may influence how likely someone is to get a COVID-19 infection. The research reveals ... Dinosaurs' Apparent ...

Apr. 8, 2025 — Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis ...

Interestingly, transgenic mice that expressed HCV core, E1, E2 and NS2 proteins were resistant to Fas antibody-stimulated ... as inactive precursor enzymes or proenzymes (see the figure).

Amgen today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or ...